RP
Richard Pazdur
Hematology & Oncology
Credentials: ·
Research
Review · The Lancet · 2014 · 3,800 citations
FDA Approval Summary: Pembrolizumab for the Treatment of Tumor Mutational Burden-High Solid Tumors
Clinical Cancer Research · 2021 · 494 citations
Review · Journal of Clinical Oncology · 1995 · 455 citations
- PK
97 papers · 1 as a fellow
- MT
81 papers
- PK
75 papers
- GB
73 papers
- AF
71 papers
- JB
40 papers
- RC
35 papers
- DS
33 papers · 1 as a fellow
